Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 6/2020

Open Access 01-12-2020 | Mites | Review

The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea?

Author: Fabienne M. N. Forton

Published in: Dermatology and Therapy | Issue 6/2020

Login to get access

Abstract

Rosacea is a common facial dermatosis but its definition and classification are still unclear, especially in terms of its links with demodicosis. Triggers of rosacea (ultraviolet light, heat, spicy foods, alcohol, stress, microbes) are currently considered to induce a cascading innate and then adaptive immune response that gets out of control. Recent histological and biochemical studies support the concept that this inflammatory response is a continuum, already present from the onset of the disease, even when no clinical signs of inflammation are visible. The Demodex mite is beginning to be accepted as one of the triggers of this inflammatory cascade, and its proliferation as a marker of rosacea; moreover, the papulopustules of rosacea can be effectively treated with topical acaricidal agents. Demodex proliferation appears to be a continuum process in rosacea, and may not be clinically visible at the onset of the disease. Molecular studies suggest that Demodex may induce tolerogenic dendritic cells and collaborate with vascular endothelial growth factor (VEGF) to induce T cell exhaustion and favor its own proliferation. These interactions among VEGF, Demodex, and immunity need to be explored further and the nosology of rosacea adapted accordingly. However, treating early rosacea, with only clinically visible vascular symptoms, with an acaricide may decrease early inflammation, limit potential flare-ups following laser treatment, and prevent the ultimate development of the papulopustules of rosacea. The effectiveness of this approach needs to be confirmed by prospective controlled clinical trials with long-term follow-up. Currently, the evidence suggests that patients with only vascular symptoms of rosacea should be carefully examined for the presence of follicular scales as signs of Demodex overgrowth or pityriasis folliculorum so that these patients, at least, can be treated early with an acaricidal cream.
Literature
1.
Tan J, Schöfer H, Araviiskaia E, et al. Prevalence of rosacea in the general population of Germany and Russia—the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428–34.PubMedPubMedCentral
2.
Cribier B. Rosacée: nouveautés pour une meilleure prise en charge. Ann Dermatol Venereol. 2017;144:508–17.PubMed
3.
Berg M, Lidén S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69:419–23.PubMed
4.
Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179:282–9.PubMed
5.
Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7:F1000 Faculty Rev-1885.
6.
Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148–55.PubMed
7.
Chen W, Plewig G. Human demodicosis: revisit and a proposed classification. Br J Dermatol. 2014;170:1219–25.PubMed
8.
Forton FM, Germaux M-AE, Thibaut SC, et al. Demodicosis: descriptive classification and status of Rosacea, in response to prior classification proposed. J Eur Acad Dermatol Venereol. 2015;29:829–32.PubMed
9.
Powell FC. Rosacea. In: Griffiths C, Barker J, Bleiker TO, Chalmers R, Creamer D, editors. Rook’s textbook of dermatology. 9th ed. 2016. Chichester: Wiley; p. 1–20.
10.
Forton FMN, De Maertelaer V. Papulopustular rosacea and rosacea-like demodicosis: two phenotypes of the same disease? J Eur Acad Dermatol Venereol. 2018;32:1011–6.PubMedPubMedCentral
11.
Saleem MD. Revisiting rosacea criteria. Dermatol Clin. 2018;36:161–5.PubMed
12.
Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584–7.PubMed
13.
Tan J, Almeida LMC, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:431–8.PubMed
14.
Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15:40–7.PubMedPubMedCentral
15.
Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975–80.PubMed
16.
17.
Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15:12–5.PubMed
18.
Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Investig Dermatol. 2011;131:688–97.PubMed
19.
Park K, Elias PM, Oda Y, et al. Regulation of cathelicidin antimicrobial peptide expression by an endoplasmic reticulum (ER) stress signaling, vitamin D receptor-independent pathway. J Biol Chem. 2011;286:34121–30.PubMedPubMedCentral
20.
Kulkarni NN, Takahashi T, Sanford JA, et al. Innate immune dysfunction in rosacea promotes photosensitivity and vascular adhesion molecule expression. J Invest Dermatol. 2020;140(645–655):e6.
21.
Salzer S, Kresse S, Hirai Y, et al. Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: possible implications for rosacea. J Dermatol Sci. 2014;76:173–9.PubMed
22.
Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Investig Dermatol. 2014;134:2728–36.PubMed
23.
Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151:1213.PubMed
24.
Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018;78:156–66.PubMed
25.
Aroni K, Tsagroni E, Lazaris AC, Patsouris E, Agapitos E. Rosacea: a clinicopathological approach. Dermatology. 2004;209:177–82.PubMed
26.
Gomaa AHA, Yaar M, Eyada MMK, Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007;34:748–53.PubMed
27.
Cribier B. Pathophysiology of rosacea: redness, telangiectasia, and rosacea. Ann Dermatol Venereol. 2011;138:S184–91.PubMed
28.
Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53–62.PubMedPubMedCentral
29.
Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21:906–10.PubMed
30.
Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol. 1969;100:683–91.PubMed
31.
Cribier B. Rosacea under the microscope: characteristic histological findings. J Eur Acad Dermatol Venereol. 2013;27:1336–43.PubMed
32.
Powell FC. The histopathology of rosacea: ‘where’s the beef?’ Dermatology. 2004;209:173–4.PubMed
33.
Lee SH, Lee SB, Heo JH, et al. Sebaceous glands participate in the inflammation of rosacea. J Eur Acad Dermatol Venereol. 2020;34:e144–6.PubMed
34.
Georgala S, Katoulis A, Kylafis G, Koumantaki-Mathioudaki E, Georgala C, Aroni K. Increased density of Demodex folliculorum and evidence of delayed hypersensitivity reaction in subjects with papulopustular rosacea. J Eur Acad Dermatol Venerol. 2001;15:441–4.
35.
Rufli T, Büchner SA. T-cell subsets in acne rosacea lesions and the possible role of Demodex folliculorum. Dermatology. 1984;169:1–5.
36.
Dajnoki Z, Béke G, Kapitány A, et al. Sebaceous gland-rich skin is characterized by TSLP expression and distinct immune surveillance which is disturbed in rosacea. J Investig Dermatol. 2017;137:1114–25.PubMed
37.
Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Investig Dermatol. 2015;135:2198–208.PubMed
38.
Brown TT, Choi E-YK, Thomas DG, Hristov AC, Chan MP. Comparative analysis of rosacea and cutaneous lupus erythematosus: histopathologic features, T-cell subsets, and plasmacytoid dendritic cells. J Am Acad Dermatol. 2014;71:100–7.PubMed
39.
Roihu T, Kariniemi A-L. Demodex mites in acne rosacea. J Cutan Pathol. 1998;25:550–2.PubMed
40.
Helm KF, Menz J, Gibson LE, Dicken CH. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol. 1991;25:1038–43.PubMed
41.
Basta-Juzbasić A, Marinović T, Dobrić I, Bolanca-Bumber S, Sencar J. The possible role of skin surface lipid in rosacea with epitheloid granulomas. Acta Med Croatica. 1992;46:119–23.PubMed
42.
Fuss F. La vie parasitaire du Demodex folliculorum hominis. Ann Derm Syph (Paris). 1933;4:1053–62.
43.
Hellerich U, Metzelder M. Incidence of scalp involvement by Demodex folliculorum Simon ectoparasites in a pathologic-anatomic and forensic medicine autopsy sample. Arch Kriminol. 1994;194:111–8.PubMed
44.
Rufli T, Mumcuoglu Y. The hair follicle mites Demodex folliculorum and Demodex brevis: biology and medical importance. Dermatology. 1981;162:1–11.
45.
Riechers R, Kopf AW. Cutaneous infestation with Demodex folliculorum in man. J Invest Dermatol. 1969;52:103–6.PubMed
46.
Nutting WB. Hair follicle mites (Acari: Demodicidae) of man. Int J Dermatol. 1976;15:79–98.PubMed
47.
Thoemmes MS, Fergus DJ, Urban J, Trautwein M, Dunn RR. Ubiquity and diversity of human-associated Demodex mites. PLoS One. 2014;9:e106265.PubMedPubMedCentral
48.
Desch C, Nutting WB. Demodex folliculorum (Simon) and D. brevis akbulatova of man: redescription and reevaluation. J Parasitol. 1972;58:169–77.PubMed
49.
Norn MS. Demodex folliculorum. Incidence, regional distribution, pathogenicity. Dan Med Bull. 1971;18:14–7.PubMed
50.
Du Bois C. Recherche du Demodex folliculorum hominis dans la peau saine. Ann Dermatol Syph. 1910:1:188–90.
51.
Zhao Y, Guo N, Xun M, Xu J, Wang M, Wang D. Sociodemographic characteristics and risk factor analysis of Demodex infestation (Acari: Demodicidae). J Zhejiang Univ Sci B. 2011;12:998–1007.PubMedPubMedCentral
52.
Nutting WB, Green AC. Pathogenesis associated with hair follicle mites (Demodex spp.) in Australian Aborigines. Br J Dermatol. 1976;94:307–12.PubMed
53.
Nutting WB, Beerman H. Demodicosis and symbiophobia: status, terminology, and treatments. Int J Dermatol. 1983;22:13–7.PubMed
54.
Gmeiner F. Demodex folliculorum des Menschen und der Tiere. Arch Derm Syphilol. 1908;92:25–96.
55.
Palopoli MF, Fergus DJ, Minot S, et al. Global divergence of the human follicle mite Demodex folliculorum: persistent associations between host ancestry and mite lineages. Proc Natl Acad Sci USA. 2015;112:15958–63.PubMedPubMedCentral
56.
Forton F, Germaux M-A, Brasseur T, et al. Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol. 2005;52:74–87.PubMed
57.
Forton FMN. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012;26:19–28.PubMed
58.
Lacey N, Russell-Hallinan A, Zouboulis CC, Powell FC. Demodex mites modulate sebocyte immune reaction: possible role in the pathogenesis of rosacea. Br J Dermatol. 2018;179:420–30.PubMed
59.
Akilov O, Mumcuoglu K. Immune response in demodicosis. J Eur Acad Dermatol Venerol. 2004;18:440–4.
60.
61.
Seyhan M, Karincaoglu Y, Bayram N, Aycan O, Kuku I. Density of Demodex folliculorum in haematological malignancies. J Int Med Res. 2004;32:411–5.PubMed
62.
Karincaoglu Y, Esrefoglu Seyhan M, Bayram N, Aycan O, Taskapan H. Incidence of Demodex folliculorum in patients with end stage chronic renal failure. Ren Fail. 2005;27:495–9.PubMed
63.
Sanchez-Viera M, Hernanz JM, Sampelayo T, Gurbindo MD, Lecona M, Soto-Melo J. Granulomatous rosacea in a child infected with the human immunodeficiency virus. J Am Acad Dermatol. 1992;27:1010–1.PubMed
64.
Sahn EE, Sheridan DM. Demodicidosis in a child with leukemia. J Am Acad Dermatol. 1992;27:799–801.PubMed
65.
Barrio J, Lecona M, Hernanz JM, et al. Rosacea-like demodicosis in an HIV-positive child. Dermatology (Basel). 1996;192:143–5.
66.
Benessahraoui M, Paratte F, Plouvier E, Humbert P, Aubin F. Demodicidosis in a child with xantholeukaemia associated with type 1 neurofibromatosis. Eur J Dermatol. 2003;13:311–2.PubMed
67.
Morrás PG, Santos SP, Imedio IL, Echeverría ML, Hermosa JMH. Rosacea-like demodicidosis in an immunocompromised child. Pediatr Dermatol. 2003;20:28–30.PubMed
68.
Herron MD, O’reilly MA, Vanderhooft SL. Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia. Pediatr Dermatol. 2005;22:407–11.PubMed
69.
Damian D, Rogers M. Demodex infestation in a child with leukaemia: treatment with ivermectin and permethrin. Int J Dermatol. 2003;42:724–6.PubMed
70.
Bañuls J, Ramon D, Aniz E, Jorda E, Torres V. Papular pruritic eruption with human immunodeficiency virus infection. Int J Dermatol. 1991;30:801–3.PubMed
71.
Jansen T, Kastner U, Kreuter A, Altmeyer P. Rosacea-like demodicidosis associated with acquired immunodeficiency syndrome. Br J Dermatol. 2001;144:139–42.PubMed
72.
de Jaureguiberry JP, Carsuzaa F, Pierre C, Arnoux D, Jaubert D. Demodex folliculitis: a cause of pruritus in human immunodeficiency virus infection. Ann Med Interne (Paris). 1993;144:63–4.
73.
Dominey A, Rosen T, Tschen J. Papulonodular demodicidosis associated with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1989;20:197–201.PubMed
74.
Ashack RJ, Frost ML, Norins AL. Papular pruritic eruption of Demodex folliculitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1989;21:306–7.PubMed
75.
Nakagawa T, Sasaki M, Fujita K, Nishimoto M, Takaiwa T. Demodex folliculitis on the trunk of a patient with mycosis fungoides. Clin Exp Dermatol. 1996;21:148–50.PubMed
76.
Redondo Mateo J, Soto Guzmán O, Fernández Rubio E, Domínguez FF. Demodex-attributed rosacea-like lesions in AIDS. Acta Derm Venereol. 1993;73:437.PubMed
77.
Aquilina C, Viraben R, Sire S. Ivermectin-responsive Demodex infestation during human immunodeficiency virus infection. Dermatology. 2002;205:394–7.PubMed
78.
Patrizi A, Trestini D, D’Antuono A, Colangeli V. Demodicidosis in a child infected with acquired immunodeficiency virus. Eur J Pediatr Dermatol. 1999;9:25–8.
79.
Duvic M. Staphylococcal infections and the pruritus of AIDS-related complex. Arch Dermatol. 1987;123:1599.PubMed
80.
Girault C, Borsa-Lebas F, Lecomte F, Humbert G. Papulonodular eruption. Demodicidosis in acquired immunodeficiency syndrome. Presse Med. 1991;20:177.PubMed
81.
Sarro RA, Hong JJ, Elgart ML. An unusual demodicidosis manifestation in a patient with AIDS. J Am Acad Dermatol. 1998;38:120–1.PubMed
82.
Antille C, Saurat J-H, Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457–60.PubMed
83.
Lübbe J, Stucky L, Saurat J-H. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology. 2003;207:205–7.
84.
Kaya OA, Akkucuk S, Ilhan G, Guneri CO, Mumcuoglu K. The importance of Demodex mites (Acari: Demodicidae) in patients with sickle cell anemia. J Med Entomol. 2019;56:599–602.PubMed
85.
Kaya S, Selimoglu MA, Kaya OA, Ozgen U. Prevalence of Demodex folliculorum and Demodex brevis in childhood malnutrition and malignancy: Demodex in malnutrition and malignancy. Pediatr Int. 2013;55:85–9.PubMed
86.
Gerber PA, Kukova G, Buhren BA, Homey B. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology. 2011;222:144–7.PubMed
87.
Molho-Pessach V, Meltser A, Kamshov A, Ramot Y, Zlotogorski A. STAT1 gain-of-function and chronic demodicosis. Pediatr Dermatol. 2020;37:153–5.PubMed
88.
Sáez-de-Ocariz M, Suárez-Gutiérrez M, Migaud M, et al. Rosacea as a striking feature in family members with a STAT1 gain-of-function mutation. J Eur Acad Dermatol Venereol. 2020;34(6):e265–7.PubMed
89.
Akdeniz S, Bahceci M, Tuzcu A, Harman M, Alp S, Bahceci S. Is Demodex folliculorum larger in diabetic patients? J Eur Acad Dermatol Venerol. 2002;16:539–41.
90.
Clifford CW, Fulk GW. Association of diabetes, lash loss, and Staphylococcus aureus with infestation of eyelids by Demodex folliculorum (Acari: Demodicidae). J Med Entomol. 1990;27:467–70.PubMed
91.
Gökçe C, Aycan-Kaya Ö, Yula E, et al. The effect of blood glucose regulation on the presence of opportunistic Demodex folliculorum mites in patients with type 2 diabetes mellitus. J Int Med Res. 2013;41:1752–8.PubMed
92.
Keskin Kurt R, Aycan Kaya O, Karateke A, et al. Increased density of Demodex folliculorum mites in pregnancies with gestational diabetes. Med Princ Pract. 2014;23:369–72.PubMedPubMedCentral
93.
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72:749–58.PubMed
94.
Perrigouard C, Peltre B, Cribier B. A histological and immunohistological study of vascular and inflammatory changes in rosacea. Ann Dermatol Venereol. 2013;140:21–9.PubMed
95.
Turgut Erdemir A, Gurel MS, Koku Aksu AE, Falay T, Inan Yuksel E, Sarikaya E. Demodex mites in acne rosacea: reflectance confocal microscopic study. Australas J Dermatol. 2017;58:e26-30.PubMed
96.
Katz AM. Rosacea: epidemiology and pathogenesis. J Cutan Med Surg. 1998;2(Suppl 4):5–10.
97.
Forton F, De Maertelaer V. Erythematotelangiectatic rosacea may be associated with a subclinical stage of demodicosis: a case–control study. Br J Dermatol. 2019;181:818–25.PubMed
98.
Zhao Y, Peng Y, Wang X, et al. Facial dermatosis associated with Demodex: a case-control study. J Zhejiang Univ Sci B. 2011;12:1008–15.PubMedPubMedCentral
99.
Forton FMN, De Maertelaer V. Rosacea and demodicosis: little-known diagnostic signs and symptoms. Acta Derm Venereol. 2019b;99:47–52.PubMed
100.
Crosti C, Menni S, Sala F, Piccinno R. Demodectic infestation of the pilosebaceous follicle. J Cutan Pathol. 1983;10:257–61.PubMed
101.
Ayres S. Pityriasis folliculorum (Demodex). Arch Derm Syphilol. 1930;21:19–24.
102.
Ayres S. demodectic eruptions (demodicidosis) in the human: 30 years’ experience with 2 commonly unrecognized entities: pityriasis folliculorum (Demodex) and acne rosacea (Demodex type). Arch Dermatol. 1961;83:816.PubMed
103.
Dominey A, Tschen J, Rosen T, Batres E, Stern JK. Pityriasis folliculorum revisited. J Am Acad Dermatol. 1989;21:81–4.PubMed
104.
Hsu C-K, Hsu MM-L, Lee JY-Y. Demodicosis: a clinicopathological study. J Am Acad Dermatol. 2009;60:453–62.PubMed
105.
Ayres S. Rosacea and rosacea-like demodicidosis. Int J Dermatol. 1987;26:198–9.PubMed
106.
Turgut Erdemir A, Gurel MS, Koku Aksu AE, et al. Reflectance confocal microscopy vs. standardized skin surface biopsy for measuring the density of Demodex mites. Skin Res Technol. 2014;20:435–9.PubMed
107.
Yun CH, Yun JH, Baek JO, Roh JY, Lee JR. Demodex mite density determinations by standardized skin surface biopsy and direct microscopic examination and their relations with clinical types and distribution patterns. Ann Dermatol. 2017;29:137.PubMedPubMedCentral
108.
Forton FMN, De Maertelaer V. Two consecutive standardized skin surface biopsies: an improved sampling method to evaluate Demodex density as a diagnostic tool for rosacea and demodicosis. Acta Derm Venereol. 2017;97:242–8.PubMed
109.
Forton FMN. Elucidating the role of Demodex folliculorum in the pathogenesis of rosacea: exciting first steps…. Br J Dermatol. 2018;179:252–3.PubMed
110.
Forton F. Demodex and perifollicular inflammation in man: review and report of 69 biopsies. Ann Dermatol Venereol. 1986;113:1047–58.PubMed
111.
Forton F, De Maertelaer V. Rosacea-like demodicosis and papulopustular rosacea may be two phenotypes of the same disease, and pityriasis folliculorum may be their precursor: response to the comment of Tatu. J Eur Acad Dermatol Venereol. 2019c;33:e47–8.PubMed
112.
Tatu AL, Clatici VG, Nwabudike LC. Rosacea-like demodicosis (but not primary demodicosis) and papulopustular rosacea may be two phenotypes of the same disease—a microbioma, therapeutic and diagnostic tools perspective. J Eur Acad Dermatol Venereol. 2019;33:e46–7.PubMed
113.
114.
Ayres S, Mihan R. Rosacea-like demodicidosis involving the eyelids. A case report. Arch Dermatol. 1967;95:63–6.PubMed
115.
Post CF, Juhlin E. Demodex folliculorum and blepharitis. Arch Dermatol. 1963;88:298–302.PubMed
116.
Morgan RJ, Coston TO. Demodex blepharitis. South Med J. 1964;57:694–9.PubMed
117.
Kim JH, Chun YS, Kim JC. Clinical and immunological responses in ocular demodecosis. J Korean Med Sci. 2011;26:1231–7.PubMedPubMedCentral
118.
Liu J, Sheha H, Tseng SCG. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010;10:505–10.PubMedPubMedCentral
119.
Purcell SM, Hayes TJ, Dixon SL. Pustular folliculitis associated with Demodex folliculorum. J Am Acad Dermatol. 1986;15:1159–62.PubMed
120.
Eismann R, Bramsiepe I, Danz B, Wohlrab J, Marsch WC, Fiedler E. Abscessing nodular demodicosis–therapy with ivermectin and permethrin. J Eur Acad Dermatol Venereol. 2010;24:79–81.PubMed
121.
Schaller M, Sander CA, Plewig G. Demodex abscesses: clinical and therapeutic challenges. J Am Acad Dermatol. 2003;49:272–4.
122.
Seifert HW. Demodex folliculorum causing solitary tuberculoid granuloma. Z Hautkr. 1978;53:540–2.PubMed
123.
Woo Y, Lim J, Cho D, Park H. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;17:1562.PubMedCentral
124.
Thyssen JP. Are Demodex mites the best target for rosacea treatments? Br J Dermatol. 2019;181:652–3.PubMed
125.
Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol. 2002;82:3–6.PubMed
126.
Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol. 2013;69:1025–32.PubMed
127.
Vemuri RC, Gundamaraju R, Sekaran SD, Manikam R. Major pathophysiological correlations of rosacea: a complete clinical appraisal. Int J Med Sci. 2015;12:387–96.PubMedPubMedCentral
128.
Grosshans E, Kremer M, Maleville J, Wanner R. Du rôle des Demodex folliculorum dans l’histogénèse de la rosacée granulomateuse. Bull Soc Fr Dermatol Syphiligr. 1972;79:639–46.
129.
Amichai B, Grunwald MH, Avinoach I, Halevy S. Granulomatous rosacea associated with Demodex folliculorum. Int J Dermatol. 1992;31:718–9.PubMed
130.
Ecker RI, Winkelmann RK. Demodex granuloma. Arch Dermatol. 1979;115:343–4.PubMed
131.
Kharfi M, Zarrouk H, Nikkels A, et al. Granulomatous rosacea and demodicidosis. Afr J Dermatol. 1991;4:39–43.
132.
Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol. 1993;128:650–9.PubMed
133.
Erbagci Z, Özgöztaşi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol. 1998;37:421–5.PubMed
134.
Chang Y-S, Huang Y-C. Role of Demodex mite infestation in rosacea: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77:441–7.PubMed
135.
Jarmuda S, McMahon F, Żaba R, et al. Correlation between serum reactivity to Demodex-associated Bacillus oleronius proteins, and altered sebum levels and Demodex populations in erythematotelangiectatic rosacea patients. J Med Microbiol. 2014;63:258–62.PubMed
136.
Tan J, Blume-Peytavi U, Ortonne JP, et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol. 2013;169:555–62.PubMed
137.
Parodi A, Guarrera M, Rebora A. Flushing in rosacea: an experimental approach. Arch Dermatol Res. 1980;269:269–73.PubMed
138.
Guzman-Sanchez DA, Ishiuji Y, Patel T, Fountain J, Chan YH, Yosipovitch G. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol. 2007;57:800–5.PubMed
139.
Voron T, Marcheteau E, Pernot S, et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 2014;4:70.PubMedPubMedCentral
140.
Voron T, Tartour É, Taieb J, Terme M. Rôle du VEGF dans l’épuisement des lymphocytes T intratumoraux. Med Sci (Paris). 2015;31:473–5.
141.
Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007;91:226–9.PubMedPubMedCentral
142.
Gazi U, Gureser AS, Oztekin A, et al. Skin-homing T-cell responses associated with Demodex infestation and rosacea. Parasite Immunol. 2019;41:e12658.PubMed
143.
Fornasa G, Tsilingiri K, Caprioli F, et al. Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. J Allergy Clin Immunol. 2015;136:413–22.PubMedPubMedCentral
144.
Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204:253–8.PubMedPubMedCentral
145.
Sim WJ, Ahl PJ, Connolly JE. Metabolism is central to tolerogenic dendritic cell function. Mediat Inflamm. 2016;2016:2636701.
146.
Hong JS, Han S, Lee JS, et al. Abnormal glucocorticoid synthesis in the lesional skin of erythematotelangiectatic rosacea. J Investig Dermatol. 2019;139(2225–2228):e3.
147.
Kanitakis J, Al-Rifai I, Faure M, Claudy A. Demodex mites of human skin express Tn but not T (Thomsen-Friedenreich) antigen immunoreactivity. J Cutan Pathol. 1997;24:454–5.PubMed
148.
Zaal A, Li RJE, Lübbers J, et al. Activation of the C-type lectin MGL by terminal GalNAc ligands reduces the glycolytic activity of human dendritic cells. Front Immunol. 2020;11:305.PubMedPubMedCentral
149.
van Vliet SJ, van Liempt E, Geijtenbeek TBH, van Kooyk Y. Differential regulation of C-type lectin expression on tolerogenic dendritic cell subsets. Immunobiology. 2006;211:577–85.PubMed
150.
van Vliet SJ, Gringhuis SI, Geijtenbeek TBH, van Kooyk Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat Immunol. 2006;7:1200–8.PubMed
151.
van Vliet SJ, Bay S, Vuist IM, et al. MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-α secretion. J Leukoc Biol. 2013;94:315–23.PubMed
152.
Li D, Romain G, Flamar A-L, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med. 2012;209:109–21.PubMedPubMedCentral
153.
Ferrer L, Ravera I, Silbermayr K. Immunology and pathogenesis of canine demodicosis. Vet Dermatol. 2014;25:427-e65.PubMed
154.
Bates J, Diehl L. Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity? J Pathol. 2014;232:112–20.PubMed
155.
Marson JW, Baldwin HE. Rosacea: a wholistic review and update from pathogenesis to diagnosis and therapy. Int J Dermatol. 2019;59(6):e175-82.PubMed
156.
Huang H-P, Hsu C-K, Lee JY-Y. Thumbnail-squeezing method: an effective method for assessing Demodex density in rosacea. J Eur Acad Dermatol Venereol. 2020;34:e343-5.PubMed
157.
Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum. J Am Acad Dermatol. 1992;26:590–3.PubMed
158.
Saleem MD, Wilkin JK. Evaluating and optimizing the diagnosis of erythematotelangiectatic rosacea. Dermatol Clin. 2018;36:127–34.PubMed
159.
Forton FMN, De Maertelaer V. Treatment of rosacea and demodicosis with benzyl benzoate: effects of different doses on Demodex density and clinical symptoms. J Eur Acad Dermatol Venereol. 2020;34:365–9.PubMed
160.
Forton FMN, De Maertelaer V. Effectiveness of benzyl benzoate treatment on clinical symptoms and Demodex density over time in patients with rosacea and demodicosis: a real life retrospective follow-up study comparing low- and high-dose regimens. J Dermatolog Treat. 2020;1–28. https://​doi.​org/​10.​1080/​09546634.​2020.​1770168.
161.
Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol. 1993;28:443–8.PubMed
162.
Abd-El-Al AM, Bayoumy AM, Abou Salem EA. A study on Demodex folliculorum in rosacea. J Egypt Soc Parasitol. 1997;27:183–95.PubMed
163.
el-Shazly AM, Ghaneum BM, Morsy TA, Aaty HE. The pathogenesis of Demodex folliculorum (hair follicular mites) in females with and without rosacea. J Egypt Soc Parasitol. 2001;31:867–75.PubMed
164.
Zhao YE, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol. 2010;146:896–902.PubMed
165.
Falay Gur T, Erdemir AV, Gurel MS, Kocyigit A, Guler EM, Erdil D. The investigation of the relationships of Demodex density with inflammatory response and oxidative stress in rosacea. Arch Dermatol Res. 2018;310:759–67.PubMed
166.
Sattler EC, Maier T, Hoffmann VS, Hegyi J, Ruzicka T, Berking C. Noninvasive in vivo detection and quantification of Demodex mites by confocal laser scanning microscopy: quantification of Demodex mites by CLSM. Br J Dermatol. 2012;167:1042–7.PubMed
167.
Tsutsumi Y. Deposition of IgD, alpha-1-antitrypsin and alpha-1-antichymotrypsin on Demodex folliculorum and D. brevis infesting the pilosebaceous unit. Pathol Int. 2004;54:32–4.PubMed
168.
Bonamigo R, Bakos L, Edelweiss M, Cartell A. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Acad Dermatol Venerol. 2005;19:646–7.
169.
Grosshans EM, Kremer M, Maleville J. Demodex folliculorum and the histogenesis of granulomatous rosacea. Hautarzt. 1974;25:166–77.PubMed
170.
Aylesworth R, Vance JC. Demodex folliculorum and Demodex brevis in cutaneous biopsies. J Am Acad Dermatol. 1982;7:583–9.PubMed
171.
Darji K, Burkemper NM. Pityriasis folliculorum: response to topical ivermectin. J Drugs Dermatol. 2017;16:1290–2.PubMed
172.
Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31:1907–11.PubMed
173.
Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments. Adv Ther. 2016;33:1481–501.PubMedPubMedCentral
174.
Gallo RL, Granstein RD, Kang S, et al. Rosacea comorbidities and future research: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:167–70.PubMed
175.
Berg M, Edström DW. Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea. Lasers Surg Med. 2004;34:266–8.PubMed
176.
177.
Say EM, Okan G, Gökdemir G. Treatment outcomes of long-pulsed Nd:YAG laser for two different subtypes of rosacea. J Clin Aesthet Dermatol. 2015;8:16–20.PubMedPubMedCentral
178.
Ertaş R, Yaman O, Akkuş MR, et al. The rapid effect of pulsed dye laser on Demodex density of facial skin. J Cosmet Laser Ther. 2019;21:123–6.PubMed
179.
Prieto VG, Sadick NS, Lloreta J, Nicholson J, Shea CR. Effects of intense pulsed light on sun-damaged human skin, routine, and ultrastructural analysis. Lasers Surg Med. 2002;30:82–5.PubMed
180.
Luo Y, Sun Y-J, Zhang L, Luan X-L. Treatment of mites folliculitis with an ornidazole-based sequential therapy: a randomized trial. Medicine. 2016;95:e4173.PubMedPubMedCentral
181.
Luo Y, Luan X-L, Zhang J-H, Wu L-X, Zhou N. Improved telangiectasia and reduced recurrence rate of rosacea after treatment with 540 nm-wavelength intense pulsed light: a prospective randomized controlled trial with a 2-year follow-up. Exp Ther Med. 2020;19:3543–50.PubMedPubMedCentral
182.
Wang P, Zhang L, Shi L, Yuan C, Zhang G, Wang X. Latent Demodex infection contributes to intense pulsed light aggravated rosacea: cases serial. J Cosmet Laser Ther. 2019;21:163–5.PubMed
183.
184.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181:65–79.PubMedPubMedCentral
185.
Del Rosso JQ, Tanghetti E, Webster G, Stein Gold L, Thiboutot D, Gallo RL. Update on the management of rosacea from the American Acne & Rosacea Society (AARS). J Clin Aesthet Dermatol. 2019;12:17–24.PubMedPubMedCentral
186.
Ayres S, Anderson NP. Acne rosacea: response to local treatment for Demodex folliculorum. JAMA. 1933;100:645–7.
187.
Hojyo Tomoka MT, Dominguez Soto L. Demodeczidosis y dermatitis rosaceiforme. Med Cutan Ibero Lat Am. 1976;4:83–90.
188.
Ayres S, Mihan R. Demodex granuloma. Arch Dermatol. 1979;115:1285–6.PubMed
189.
Pietrini P, Favennec L, Brasseur P. Demodex folliculorum in parakeratosis of the scalp in a child. Parasite. 1995;2:94.PubMed
190.
Patrizi A, Neri I, Chieregato C, Misciali M. Demodicidosis in immunocompetent young children: report of eight cases. Dermatology (Basel). 1997;195:239–42.
191.
Junk AK, Lukacs A, Kampik A. Topical administration of metronidazole gel as an effective therapy alternative in chronic Demodex blepharitis—a case report. Klin Monbl Augenheilkd. 1998;213:48–50.PubMed
192.
Ivy SP, Mackall CL, Gore L, Gress RE, Hartley AH. Demodicidosis in childhood acute lymphoblastic leukemia; an opportunistic infection occurring with immunosuppression. J Pediatr. 1995;127:751–4.PubMed
193.
Fulk GW, Murphy B, Robins MD. Pilocarpine gel for the treatment of demodicosis—a case series. Optom Vis Sci. 1996;73:742–5.PubMed
194.
Celorio J, Fariza-Guttmann E, Morales V. Pilocarpine as a coadjuvant treatment of blepharoconjunctivitis caused by Demodex folliculorum. Invest Ophtalmol Vis Sci. 1988;30(suppl):40.
195.
Harmelin Y, Delaunay P, Erfan N, Tsilika K, Zorzi K, Passeron T, Lacour JP, Bahadoran P. Interest of confocal laser scanning microscopy for the diagnosis and treatment monitoring of demodicosis. J Eur Acad Dermatol Venerol. 2014;28(2):255–7.
196.
Rufli T, Mumcuoglu Y, Cajacob A, Büchner S. Demodex folliculorum: aetiopathogenesis and therapy of rosacea and perioral dermatitis (author’s transl). Dermatologica. 1981;162:12–26.PubMed
197.
Hoekzema R, Hulsebosch HJ, Bos JD. Demodicidosis or rosacea: what did we treat? Br J Dermatol. 1995;133:294–9.PubMed
198.
Varotti C, Ghetti P, Negosanti M, Passarini B. Demodex folliculorum ed acne rosacea. G Ital Dermatol Venereol. 1981;116:489–91.
199.
De Dulanto F, Camacho-Martinez F. Demodicidosis gravis. Ann Dermatol Venereol. 1979;106:699–704.PubMed
200.
Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41:775–7.PubMed
201.
Kito Y, Hashizume H, Tokura Y. Rosacea-like demodicosis mimicking cutaneous lymphoma. Acta Derm Venerol. 2012;92:169–70.PubMed
202.
García-Vargas A, Mayorga-Rodríguez JA, Sandoval-Tress C. Scalp demodicidosis mimicking favus in a 6-year-old boy. J Am Acad Dermatol. 2007;57:S19-21.PubMed
203.
Aydogan K, Alver O, Tore O, Karadogan S. Facial abscess-like conglomerates associated with Demodex mites. J Eur Acad Dermatol Venerol. 2006;20(8):1002–4.
204.
Shelley WB, Shelley ED, Burmeister V. Unilateral demodectic rosacea. J Am Acad Dermatol. 1989;20:915–7.PubMed
205.
Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol. 2009;2:20–5.PubMedPubMedCentral
206.
Brown M, Hernández-Martín A, Clement A, Colmenero I, Torrelo A. Severe Demodex folliculorum-associated oculocutaneous rosacea in a girl successfully treated with ivermectin. JAMA Dermatol. 2014;150:61.PubMed
207.
Vashisht D, Singh J, Baveja S, Tiwari R, Bhatnagar A. Unilateral demodicidosis of face mimicking Hansens disease. Dermatol Reports. 2016;8:6891.PubMedPubMedCentral
208.
Pallotta S, Cianchini G, Martelloni E, et al. Unilateral demodicidosis. Eur J Dermatol. 1998;8:191–2.PubMed
209.
Norn MS. Demodex folliculorum. Incidence and possible pathogenic role in the human eyelid. Acta Ophthalmol Suppl. 1970;108:7–85.PubMed
210.
Gao Y-Y, Di Pascuale MA, Li W, et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol. 2005;89:1468–73.PubMedPubMedCentral
211.
212.
Tighe S, Gao Y-Y, Tseng SCG. Terpinen-4-ol is the most active ingredient of tea tree oil to kill Demodex mites. Trans Vis Sci Tech. 2013;2:2.
213.
Persi A, Rebora A. Metronidazole and Demodex folliculorum. Acta Derm Venereol. 1981;61:182–3.PubMed
214.
Koo H, Kim TH, Kim KW, Wee SW, Chun YS, Kim JC. Ocular surface discomfort and Demodex: effect of tea tree oil eyelid scrub in Demodex blepharitis. J Korean Med Sci. 2012;27:1574–9.PubMedPubMedCentral
215.
Evren Kemer Ö, Karaca EE, Özek D. Efficacy of cyclic therapy with terpinen-4-ol in Demodex blepharitis: Is treatment possible by considering Demodex’s life cycle? Eur J Ophthalmol. 2020;1120672120919085.
216.
Lam NSK, Long XX, Griffin RC, Chen M-K, Doery JC. Can the tea tree oil (Australian native plant: Melaleuca alternifolia Cheel) be an alternative treatment for human demodicosis on skin? Parasitology. 2018;145:1510–20.PubMed
217.
Persi A, Rebora A. Metronidazole in the treatment of rosacea. Arch Dermatol. 1985;121:307–8.
218.
Forton S, Marchal S. Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy. Br J Dermatol. 1998;138:461–6.PubMed
219.
Salem DAB, El-Shazly A, Nabih N, El-Bayoumy Y, Saleh S. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis. 2013;17:e343-7.PubMed
220.
Raoufinejad K, Mansouri P, Rajabi M, Naraghi Z, Jebraeili R. Efficacy and safety of permethrin 5% topical gel vs. placebo for rosacea: a double-blind randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2016;30:2105–17.PubMed
221.
Koçak M, Yağli S, Vahapoğlu G, Ekşioğlu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology (Basel). 2002;205:265–70.
222.
Jacob S, VanDaele MA, Brown JN. Treatment of Demodex-associated inflammatory skin conditions: a systematic review. Dermatol Ther. 2019;32:e13103.PubMed
223.
Siddiqui K, Gold LS, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. SpringerPlus. 2016;5:1151.PubMedPubMedCentral
224.
Stein Gold L, Kircik L, Fowler J, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13:1380–6.PubMed
225.
Ali ST, Alinia H, Feldman SR. The treatment of rosacea with topical ivermectin. Drugs Today. 2015;51:243.
226.
Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172:1103–10.PubMed
227.
Schaller M, Dirschka T, Kemény L, Briantais P, Jacovella J. Superior efficacy with ivermectin 1% cream compared to metronidazole 0.75% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb). 2016;6:427–36.
228.
Schaller M, Schöfer H, Homey B, et al. Rosacea management: update on general measures and topical treatment options. J Dtsch Dermatol Ges. 2016;14(Suppl 6):17–27.PubMed
229.
van Zuuren EJ, van der Linden MMD, Arents BWM. Rosacea treatment guideline for the Netherlands. Br J Dermatol. 2020;182:1504–6.PubMedPubMedCentral
230.
Trave I, Merlo G, Cozzani E, Parodi A. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther. 2019;32:e13093.PubMed
231.
Schaller M, Kemény L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82:336–43.PubMed
232.
233.
Cardwell L, Alinia H, Moradi Tuchayi S, Feldman S. New developments in the treatment of rosacea—role of once-daily ivermectin cream. Clin Cosmet Investig Dermatol. 2016;9:71–7.PubMedPubMedCentral
234.
Abokwidir M, Fleischer AB. Additional evidence that rosacea pathogenesis may involve Demodex: new information from the topical efficacy of ivermectin and praziquantel. Dermatol Online J. 2015;21:13030/qt13v249f5.
235.
Abokwidir M, Fleischer AB. An emerging treatment: topical ivermectin for papulopustular rosacea. J Dermatolog Treat. 2015;26:379–80.PubMed
236.
Ruini C, Sattler E, Hartmann D, Reinholz M, Ruzicka T, von Braunmühl T. Monitoring structural changes in Demodex mites under topical ivermectin in rosacea by means of reflectance confocal microscopy: a case series. J Eur Acad Dermatol Venereol. 2017;31:e299-301.PubMed
237.
Trompezinski S, Pernet I, Schmitt D, Viac J. UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res. 2001;50:422–7.PubMed
238.
Brauchle M, Funk JO, Kind P, Werner S. Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem. 1996;271:21793–7.PubMed
239.
Stromberg BE, Nutting WB. Adaptive features of the exoskeleton and pigment deposits in Demodex spp. (Demodicidae). Acarologia. 1973;14:605–11.
240.
Clanner-Engelshofen BM, French LE, Reinholz M. Corynebacterium kroppenstedtii subsp. demodicis is the endobacterium of Demodex folliculorum. J Eur Acad Dermatol Venereol. 2020;34:1043–9.PubMed
241.
Akilov OE, Butov YS, Mumcuoglu KY. A clinico-pathological approach to the classification of human demodicosis. Ein klinisch-pathologischer Ansatz zur Klassifikation der humanen Demodikose. J Deut Dermatol Gesell. 2005;3:607–14.
242.
Sędzikowska A, Osęka M, Grytner-Zięcina B. Ocular symptoms reported by patients infested with Demodex mites. Acta Parasitol. 2016;61:808–14.PubMed
Metadata
Title
The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea?
Author
Fabienne M. N. Forton
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 6/2020
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-020-00458-9

Other articles of this Issue 6/2020

Dermatology and Therapy 6/2020 Go to the issue

Original Research

Skin Recovery After Discontinuation of Long-Term Moisturizer Application: A Split-Face Comparison Pilot Study

Letter

Response to Letter to the Editor Regarding “A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc® Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts”

Original Research

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis

Original Research

Night Cream Containing Melatonin, Carnosine and Helichrysum italicum Extract Helps Reduce Skin Reactivity and Signs of Photodamage: Ex Vivo and Clinical Studies

Original Research

Psoriasis is Associated with a High Comedication Burden: A Population Based Register Study

Original Research

Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits